Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study

BACKGROUND: Real-world relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) populations may be more diverse than in clinical trials. Here, we present a first analysis of safety, adherence and persistence data from a real-world cohort of patients newly treated with ocrelizumab. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Martin S., Buttmann, Mathias, Meuth, Sven G., Dirks, Petra, Muros-Le Rouzic, Erwan, Eggebrecht, Julius C., Hieke-Schulz, Stefanie, Leemhuis, Jost, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126090/
https://www.ncbi.nlm.nih.gov/pubmed/35614917
http://dx.doi.org/10.3389/fneur.2022.863105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126090/
https://www.ncbi.nlm.nih.gov/pubmed/35614917
http://dx.doi.org/10.3389/fneur.2022.863105

Ejemplares similares